Inhibrx Biosciences posts Q3 net loss of $35.3 million

Inhibrx Biosciences Inc. reported a net loss of $35.3 million, or $2.28 per share, basic and diluted, for the third quarter of 2025, compared to a net loss of $43.9 million, or $2.84 per share, for the same period in 2024. Research and development expenses were $28.5 million, down from $38.9 million in the third quarter of 2024, primarily due to decreased process development, manufacturing activities, and lower personnel-related expenses. Cash and cash equivalents totaled $153.1 million as of September 30, 2025, compared to $186.6 million as of June 30, 2025. Other expense was $1.4 million, versus other income of $2.9 million in the same period last year, mainly due to interest expense on outstanding debt. During the period, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and interim data from expansion cohorts in colorectal cancer and Ewing sarcoma. The company plans to submit a biologics license application for ozekibart to the FDA in the second quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24318) on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)